Dopamine agonists and their role in Parkinson’s disease treatment

References

• Jankovic J, Marsden CD. Therapeutic strategies in Parkinson's disease. In: Parkinson, Disease and Movement Disorders. Third Edition. Jankovic J, Tolosa E (Eds). Williams and Wilkins, MD, USA, 191–220 (1998).
   Google Scholar
• Management of Parkinson's disease: an evidence-based review. May Disotyl 17\(Suppl. 4), S1—S166 (2002).
   Google Scholar
• •Evidence-based review on the management of Parkinson's disease (PM
   Google Scholar
• Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 18 (6), 389–396 (2001).
   Google Scholar
• Tan EK. Parkinson's disease surgery: advances and future strategies. int. j Gun. Pratt 53(8), 623–626 (1999).
   Google Scholar
• Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neural 53\(Suppl. 3), S87—S99 (2003).
   Google Scholar
• Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet359(9317), 1589–1598 (2002).
   PubMed Web of Science ®Google Scholar
• •Evidence-based review on the management of PD.
   Google Scholar
• Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin. Neuropharmacol 24(5), 247–253 (2001).
   PubMed Web of Science ®Google Scholar
• Bennett JP Jr, Piercey ME Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease. J. Neural Sci. 163(1), 25–31 (1999).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engif Med. 18, 1484–1491 (2000).
   Google Scholar
• Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 284,1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Olanow W Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci.10(Suppl.), S117—S126 (2000).
   Google Scholar
• Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neural 44, S167—S174 (1998).
   Google Scholar
• Hanna PA, Ratkos L, Ondo WG, Jankovic J. A comparison of the therapeutic efficacy of pergolide and pramipexole in Parkinson's disease. J. Neural. Transm. 108, 63–70 (2001).
   PubMed Web of Science ®Google Scholar
• Korczyn AD, Brunt ER, Larsen JP eta]. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology53, 364–370 (1999).
   Google Scholar
• Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease: is fast titration preferable to slow? Neurology52,1227–1229 (1999).
   Google Scholar
• Canesi M, Antonini A, Mariani CB eta]. An overnight switch to ropinirole therapy in patients with Parkinson's disease. J. Neural. Transm. 106,925–929 (1999).
   PubMed Web of Science ®Google Scholar
• Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol 0, Stocchi E Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. May Disotyl 13,46–51 (1998).
   Google Scholar
• Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology49, 1060–1065 (1997).
   Google Scholar
• Inzelberg R, Nisipeanu P, Rabey JM et al Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology47,785–788 (1996).
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 45, S13—S21 (1995).
   Google Scholar
• Pezzoli G, Martignoni E, Pacchetti C eta! Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. May Disotyl 9, 431–436 (1994).
   PubMed Web of Science ®Google Scholar
• Laihinen A, Rinne UK, Suchy I. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease. Acta Neural Stand. 86,593–595 (1992).
   Google Scholar
• Goetz CG, Shannon KM, Tanner CM, Carroll VS, Klawans HL. Agonist substitution in advanced Parkinson's disease. Neurology 39,1121–1122 (1989).
   Google Scholar
• Goetz CG, Tanner CM, Glantz RII, KLawans HL. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neumlogy 35,749–751 (1985).
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Ward CD, Larsen TA eta! Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology33, 1009–1014 (1983).
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Gopinathan G, Ward CD et al Lisuride versus bromocriptine treatment in Parkinson's disease: a double-blind study. Neurology32, 69–72 (1982).
   PubMed Web of Science ®Google Scholar
• Clarke CE, Deane KD. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev. (1), CD001519 (2001).
   Google Scholar
• Corrigan MET, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress. Anxiety11,58–65 (2000).
   PubMed Web of Science ®Google Scholar
• Ondo W, Hunter C, Almaguer M, Jankovic J. Sublingual apomorphine in patients with fluctuating Parkinson's disease. May Disotyl 14,664–668 (1999).
   PubMed Web of Science ®Google Scholar
• Calabrese VP, Lloyd IKA, Brancazio P et al N-0923, a novel soluble dopamine D2 in the treatment of parkinsonism. May Disorcl. 13,768–774 (1998).
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Ziegler M, Rascol 0 eta]. A randomized, double-blind study of a skin patch of a dopaminergic agonist, Piribedil, in Parkinson's disease. May Disorcl 14,336–341 (1999).
   Google Scholar
• Tan EK, Ratnagopal P, Han SY, Wong MC. Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study. Acta Neural. Scant! 107(3), 202–206 (2003).
   Google Scholar
• Lund BC, Neiman RF, Perry PJ. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Pharmacotherapy19, 1437–1438 (1999).
   Google Scholar
• Tan EK, Ondo W Clinical characteristics of pramipexole-induced peripheral oedema. Arch. Neural. 57, 729–732 (2000).
   PubMed Web of Science ®Google Scholar
• Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neumlogy52, 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Tan EK, Lum SY, Fook-Chong SM et al Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology58(3), 465–468 (2002).
   PubMed Web of Science ®Google Scholar
• Tan EK. Piribedil-induced sleep attacks in Parkinson's disease. Funclam. Clin. Pharmacol. 17(1), 117–119 (2003).
   Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson's disease progression. JAMA 287(13), 1653–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ eta! Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neural. 54(1), 93–101 (2003).
   Google Scholar
• Schapira AH, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann. Neural. 53\(Suppl. 3), S149—S59 (2003).
   Google Scholar
• •Useful review on functioning imaging and laboratory studies.
   Google Scholar
• Schapira AH. Neuroprotection and dopamine agonists. Neumlogy58(4 Suppl. 1), S9—S18 (2002).
   Google Scholar
• •Useful review on functioning imaging and laboratory studies.
   Google Scholar
• Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. Neural. Transm. 104, 209–228 (1997).
   Google Scholar
• Nishibayashi S, Asanuma M, Kohno M, Gomez-Vargas M, Ogawa N. Scavenging effects of dopamine agonists on nitric oxide radicals. Neurochem. 67, 2208–2211 (1996).
   Google Scholar
• Sawada H, Ibi M, Kihara T et a/. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neural. 45, 110–119 (1998).
   Google Scholar
• Muralikrishnan D, Mohanakumar IQ. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEBJ 12, 905–912 (1998).
   PubMed Web of Science ®Google Scholar
• Gassen M, Gross A, Youdim MB. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2 02 and 6-hydroxydopamine. May Disarl. 13, 661–667 (1998).
   Google Scholar
• Ubeda A, Montesinos C, Paya M eta]. Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free. Raclin Biol. Med. 15, 159–167 (1993).
   PubMedGoogle Scholar
• Ogawa N, Tanaka K, Asanuma M eta! Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro. Brain Res. 657, 207–213 (1994).
   PubMed Web of Science ®Google Scholar
• Zou L, Xu J, Jankowic J, He Y, Appel SH, Le W Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci. Lett. 281, 167–170 (2000).
   Google Scholar
• King DF, Cooper JM, Schapira AHV. Pramipexole protects against MPP+ toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. Neumlogy56, A377—A388 (2001).
   Google Scholar
• Kitamura Y, Kosaka T, Kakimura JI eta]. Protective effects of the antiparkinsoniam drugs telipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-575Y cells. Mal. Pharmacol. 54, 1046–1054 (1998).
   Google Scholar
• Cassarino DS, Fall CP, Smith TS, Bennet JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neumchem. 71, 295–301 (1998).
   Google Scholar
• Zou L, Jankowic J, He Y, Appel SH, Le W Neuroprotection by pramipexole against dopamine and levodopa-induced cytotoxicity. Life Sri. 64, 1275–1285 (1999).
   PubMed Web of Science ®Google Scholar
• Ling ZD, Robie HC, Tong CW, Carvey PM. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J. Pharmacol. Exp. Ther. 289, 203–210 (1999).
   Google Scholar
• Takashima H, Tsujihata M, Kishikawa M, Freed WJ. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp. Neural. 159, 98–104 (1999).
   Google Scholar
• Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neumlogy60(3), 381–389 (2003).
   PubMed Web of Science ®Google Scholar